Your session is about to expire
← Back to Search
Obinutuzumab for Follicular Lymphoma
Study Summary
This trial is studying obinutuzumab given as a short duration infusion for safety in patients with untreated advanced follicular lymphoma.
- Follicular Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 229 Patients • NCT02264574Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment for this clinical exploration still accessible?
"According to clinicaltrials.gov, patient recruitment for this experiment has been concluded; the protocol was first posted on February 26th 2019 and last modified November 21st 2022. However, there are currently 3122 other trials requiring participants at present."
Is this experiment the initial foray into its kind of research?
"At present, 1402 studies for Obinutuzumab are ongoing in 81 countries and 3024 cities. Alfacell's 1997 study was the earliest to include this drug; it involved 300 participants across its Phase 3 approval stages. In total, 2359 trials have been satisfactorily concluded since then."
What are the more prevalent maladies that Obinutuzumab has been employed to address?
"Pheochromocytomas are typically treated with Obinutuzumab, a drug that is also able to help manage ulcerative colitis, varicella-zoster virus acute retinal necrosis and multiple myeloma."
How many participants has this clinical trial recruited?
"This study is not currently seeking participants, as its last update was on November 21st 2022. If you are looking to join a clinical trial dealing with lymphoma or Obinutuzumab there are 1720 and 1402 trials respectively that need volunteers right now."
Has Obinutuzumab been tested in prior medical investigations?
"Currently, there are 1,402 clinical trials centered around Obinutuzumab with 309 in the final phase of study. While Bethesda Maryland has a significant number of these studies underway, overall 53146 sites have participated in research surrounding this drug."
What is the prevalence of hospitals administering this clinical test in the city?
"This trial is taking place at 12 different centers, including Center For Cancer and Blood Disorders in Bethesda, Texas Onc-Central Austin CA Ct in Austin, Rocky Mountain Cancer Center; Medical Oncology in Boulder and 9 other medical facilities."
What potential risks might be associated with Obinutuzumab use?
"Due to the fact that Obinutuzumab is a Phase 4 treatment, meaning it has already been approved for public use, our team at Power rated its safety as 3."
Share this study with friends
Copy Link
Messenger